*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# PW MEDTECH GROUP LIMITED

# 普华和顺集团公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1358)**

## APPOINTMENT OF NON-EXECUTIVE DIRECTORS

The board of directors (the "**Board**") of PW Medtech Group Limited (the "**Company**") announces that Mr. Li Ronghui ("**Mr. Li**") and Mr. Liu Zhifei ("**Mr. Liu**") have been appointed as additional non-executive directors of the Company with effect from December 1, 2026.

The biographical details of Mr. Li and Mr. Liu are set out as follows:

Mr. Li Ronghui (李榮輝), aged 55, has over 10 years of investment experience and approximately 20 years of management experience in different industries such as environmental protection, analytical instrument and electric vehicle. Currently, as an investor, Mr. Li maintains investments in consuming field and IT industries. Mr. Li also acts as general partner for investment projects such as Pingxiang Yukuan Enterprise Management Partnership (萍鄉昱寬企業管理合夥企業), which is one of the main shareholders of a promising enterprise in IT industry. Mr. Li was the Vice Director of Investment Department of Beijing Zhunxing Longbo Investment Co., Ltd. (北京准興隆博投資有限公司) from March 2013 to March 2017. Before that he was the Senior Manager of Beijing Sentech Environmental Technology Co., Ltd. (北京晟德瑞環境技術有限公司) from August 2000 to January 2013. Mr. Li obtained a master's degree in business administration from Beijing University of Technology (北京工業大學) in July 2012. He also obtained the Fund Practitioner Qualification Certificate by the Asset Management Association of China in 2016.

Mr. Li has confirmed to the Company that, as at the date of this announcement, he (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**"); (ii) does not hold any other positions with the Company or other members of the Group; (iii) did not hold any directorship in the last three years in any public company, the securities of which are listed on any securities market in Hong Kong or overseas, nor other major appointments and professional qualifications; and (iv) does not have any relationship with any Director, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company.

Mr. Liu Zhifei (劉之斐), aged 39, has over 15 years of experience in financial services industry and has 10 years of experience in biotechnology investments in China and globally. Mr. Liu currently serves as the Partner of Probitas Capital Investment Advisory (Hong Kong) Limited (謙和資本投資諮詢 (香港) 有限公司). Prior to that, Mr. Liu worked for ORI Capital Limited (新元資本有限公司), The Blackstone Group (HK) Limited (黑石集團 (香港) 有限公司), Goldman Sachs (Asia) L.L.C. (高盛 (亞洲) 有限責任公司) and Goldman Sachs Australia Pty Ltd. Mr. Liu has been serving as an independent

non-executive director of Hanwei Electronics Group Corporation (漢威科技集團股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300007), since February 2026. Mr. Liu obtained Bachelor of Law and Bachelor of Commerce (Honours) Degrees from the University of Melbourne.

Mr. Liu has confirmed to the Company that, as at the date of this announcement, he (i) does not have any interests in the shares of the Company within the meaning of Part XV of the SFO; (ii) does not hold any other positions with the Company or other members of the Group; (iii) save as disclosed above, did not hold any directorship in the last three years in any public company, the securities of which are listed on any securities market in Hong Kong or overseas, nor other major appointments and professional qualifications; and (iv) does not have any relationship with any Director, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, there is no other information relating to the appointment of Mr. Li and Mr. Liu that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, nor are there any other matters relating to their appointments that needs to be brought to the attention of the Shareholders.

The appointment of Mr. Li and Mr. Liu has been recommended by the nomination committee of the Company and approved by the Board. The term of office of each of Mr. Li and Mr. Liu shall be three years commencing on December 1, 2026. Mr. Li and Mr. Liu are also subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association. As such, pursuant to the third amended and restated memorandum and articles of association of the Company (the "**Articles of Association**"), Mr. Li and Mr. Liu shall each hold office until the first annual general meeting of the Company (the "**AGM**") after their appointment, and be subject to re-election by the shareholders of the Company at the AGM. Mr. Li and Mr. Liu will each be entitled to a director's fee of HK$200,000 per annum pursuant to the letters of appointment which will be entered into between the Company and each of Mr. Li and Mr. Liu for their service as non-executive Directors which has been determined by the Board with the recommendation of the remuneration committee of the Company with reference to their (i) skills, knowledge and experience; (ii) roles and duties; and (iii) the prevailing market conditions. The emoluments of Mr. Li and Mr. Liu are subject to revision in future by the decision of the Board based on the recommendation of the remuneration committee of the Company.

The Board would like to extend a warm welcome to Mr. Li and Mr. Liu for joining the Board.

By Order of the Board
**PW Medtech Group Limited**
**Yue'e Zhang**
*Chairman & Chief Executive Officer*

Hong Kong, November 27, 2026

*As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue'e Zhang; two non-executive Directors, namely, Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.*